Antibiotics are not always enough for Staph bloodstream infections. Can Armata turn bacteriophages into an FDA-approved adjunct?
FDA grants Breakthrough Therapy status to Armata’s AP-SA02 after randomized data support bacteriophage therapy in complicated Staph bacteremia.